Comparative Pharmacology
Head-to-head clinical analysis: FOSCAVIR versus ZIRGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSCAVIR versus ZIRGAN.
FOSCAVIR vs ZIRGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Foscarnet is a pyrophosphate analog that selectively inhibits viral DNA polymerase and reverse transcriptase by binding to the pyrophosphate binding site, preventing the cleavage of pyrophosphate from deoxynucleotide triphosphates, thereby inhibiting viral DNA synthesis. It does not require activation by viral thymidine kinase, making it active against acyclovir-resistant HSV and VZV, and ganciclovir-resistant CMV.
Ganciclovir is a synthetic guanine derivative that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) and by incorporating into viral DNA, causing chain termination. Ganciclovir is phosphorylated to ganciclovir triphosphate by viral thymidine kinase (UL97) in CMV-infected cells.
Induction: 60 mg/kg IV every 8 hours for 2-3 weeks, then maintenance: 90-120 mg/kg IV once daily. Administer as a 2-hour infusion via central line.
Instill 1 drop (approximately 0.05 mL) into affected eye(s) 5 times daily (approximately every 3 hours while awake) until corneal ulcer heals, then reduce to 1 drop 3 times daily for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 3-5 hours in patients with normal renal function; can extend to 48-120 hours in severe renal impairment (CrCl <20 mL/min), requiring dose adjustment and therapeutic drug monitoring.
Terminal elimination half-life in patients with normal renal function is approximately 3-4 hours; in renal impairment, half-life may be prolonged up to 30 hours, requiring dose adjustment.
Primarily renal excretion (>80% as unchanged drug) via glomerular filtration and tubular secretion; minimal biliary/fecal elimination (<5%).
Primarily renal excretion as unchanged drug via glomerular filtration and tubular secretion; >90% of a systemically absorbed dose is recovered unchanged in urine.
Category C
Category C
Antiviral
Antiviral